Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review
Lapatinib, an orally administered small-molecule tyrosine kinase inhibitor (SM-TKI), is an effective treatment for ErbB2-positive breast cancer. However, its efficacy as one of the targeted cancer therapies has been hampered by several adverse effects, especially gastrointestinal toxicity, commonly...
| Published in: | BioMed Research International |
|---|---|
| Main Author: | |
| Format: | Review |
| Language: | English |
| Published: |
Hindawi Limited
2022
|
| Online Access: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133610403&doi=10.1155%2f2022%2f4165808&partnerID=40&md5=b2db8a2d05dc4eac4e5b45cdad0fbdb5 |